Home » AiCuris’ innovation program AiCubator enters the third round with the call for innovative projects to promote the development of new anti-infectives

AiCuris’ innovation program AiCubator enters the third round with the call for innovative projects to promote the development of new anti-infectives

by archyde

EQS-News: AiCuris Anti-infective Cures AG / Key word(s): Miscellaneous

AiCuris Anti-infective Cures AG: AiCuris’ innovation program AiCubator enters the third round with the tender for innovative projects to promote the development of new anti-infectives

29.09.2022 / 09:03 CET/EST
The issuer / publisher is responsible for the content of the notification.

AiCuris’ Innovation program AiCubator enters the third round with the tender for innovative projects to promote the development of new anti-infectives

  • The AiCubator program was created to support first-hand early research projects by young start-ups and academic teams that have the potential to become the next generation of resistance-breaking anti-infectives
  • Up to three projects will receive AiCubator resident status and benefit from the company’s financial support and scientific know-how, its proven expertise in drug development and its extensive network in the life science industry over a period of three years
  • The application phase for the AiCubator starts on October 1st and runs until December 31st, 2022

Wuppertal, 29. September 2022 – AiCuris Anti-infective Cures AG, a leading clinical-stage pharmaceutical company developing novel, resistance-breaking antiviral and antibacterial agents for the treatment of serious and potentially life-threatening infectious diseases, today announced the launch of the third round of its innovative funding program “AiCubator”.

The AiCubator was launched by AiCuris in 2020. It aims to support the development of early first-hand research projects that, with their innovations and based on scientific principles, can address infectious diseases with high unmet medical needs, combat antibiotic resistance and prevent future pandemics. The selected AiCubator residents will benefit over a period of up to three years from the scientific know-how and expertise in drug development of AiCuris, one of the leading companies in the field of anti-infectives with one product already on the market. As part of the AiCubator program, residents learn how to turn their great ideas into new products. You will receive support in developing a clear strategy, a stringent timetable and preparing a convincing presentation of the results that have already been obtained. These are all important skills to help young startups accelerate their success and enhance future funding and licensing opportunities. In addition, the nominated research groups and biotech founders will receive financial support and access to AiCuris’ extensive international network of renowned scientific partners, associations and service providers as well as other leading pharmaceutical and biotechnology companies.

Applications for the AiCubator program can be submitted online using the AiCubator application form. There is an opportunity to describe the project, its status and the development plans. For more information about the program, visit the AiCuris AiCubator website.

“What has really excited me since the beginning of our AiCubator program is the abundance of extraordinary ideas that are developed every day in academia or in young biotechnology companies. However, many of these ideas fail because of too little business and development experience and not most recently due to a lack of funding,” said dr Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG. “At AiCuris, we strongly believe that there is an urgent need to advance these ideas at a very early stage in order to close pipeline gaps, fight antibiotic resistance and prevent future pandemics. We are constantly on the lookout for novel technologies and approaches that have the potential to make a real difference in the treatment of infectious diseases for which there are few or no therapies today to accompany for the next few years.”

Academic groups from a university, institute and also biotech start-ups who are at the beginning of their path and working on antiviral or antibacterial research projects or early preclinical development programs are invited to apply for the AiCubator program. The focus of the initiative is on targeted antiviral and antibacterial therapies and applications in the following indications:

  • Antiviral therapies used to treat:
    • Hepatitis B Virus (HBV Cure)
    • HIV Cure
    • BK-Virus
    • Epstein-Barr-Virus
    • Adenovirus
    • Pan-Herpesvirus
    • Norovirus
    • Solutions for pandemic preparedness (RSV, pan-respiratory viruses)
  • Antibacterial therapies beyond “small molecules” to treat:
    • Bloodstream infections
    • Diabetic foot infections
    • Antimicrobial Resistance
    • Osteomyelitis
  • Novel platform approach to infectious diseases

The submitted projects will be evaluated by AiCuris experts based on various criteria – including the status of target identification and initial efficacy data as well as the indications addressed and potential advantages over existing treatment standards. Each year, AiCuris awards up to three projects that are scientifically attractive but too early for licensing agreements with “AiCubator Resident Status”.

Important dates and deadlines:

Submission Deadline:October 01 to December 31, 2022, midnight CET
Announcement of the winning projects:April 2023

About AiCubator

To support early ideas that could lead to the next resistance-breaking antibiotic or anti-infective, each year AiCuris selects promising research projects for the AiCubator, the company’s innovative funding program. The AiCubator initiative is aimed at academic research groups or recently founded biotechnology start-ups with early-stage anti-infective projects in important research areas that are scientifically interesting but not yet mature enough to be licensed. The program is designed to support scientists and startups to build their own company and to further develop the underlying ideas and approaches to an advanced status. Participants in the AiCubator program will receive long-term support from AiCuris, including financial, scientific, regulatory, and business development advice. In addition, they get insights into preclinical and clinical drug research and the pharmaceutical business.

For more information on the AiCubator, visit: www.aicuris.com/AiCubator.
Follow AiCubator on LinkedIn and Twitter.

About AiCuris Anti-infective Cures AG

AiCuris, a clinical-stage biopharmaceutical company, was founded in 2006 as a spin-off from Bayer AG and focuses on the discovery and development of drugs against infectious diseases. PREVYMIS (Letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor that exerts its action through a novel mechanism, was out-licensed to MSD in 2012 and has distribution in the EU, US, Japan and marketing authorization in other parts of the world for the prevention of CMV infection in adult allogeneic hematopoietic stem cell transplant (HSCT) recipients. The Company has a broad pipeline of clinical and preclinical antiviral and antibacterial study programs. The lead proprietary candidate pritelivir for the treatment of herpes simplex virus (HSV) infections with single and double resistance is in phase 3 of clinical development. The company is also working on other drug candidates against viruses such as the hepatitis B virus (HBV), adenoviruses, BK virus (BKV) and against SARS-CoV-2 and other viruses with pandemic potential. In the field of antibacterial agents, AiCuris focuses on researching innovative treatment options for indications with a high unmet medical need, such as life-threatening (multi-)resistant hospital pathogens. Further innovative therapy concepts against antimicrobial resistance (AMR) and for the treatment of diabetic foot and sepsis are in preclinical testing.

AiCuris is backed by a strong shareholder base led by its main investor SANTO Holding.

For more information about the company, visit www.aicuris.com.
Follow us on LinkedIn.


AiCuris Anti-infective Cures AG
Katja Woestenhemke
Phone: +49 202 317 63 0
E-Mail: [email protected]
media work
MC Services AG
Dr. Solveigh Mähler
Phone: +49 211 529 252 19
E-Mail: [email protected]
Andreas Kühbacher, PhD
Phone: +49 202 317 63 0
E-Mail [email protected]

09/29/2022 CET/CEST Release of a Corporate News/Financial News, transmitted by EQS – a service of EQS Group AG.
The issuer / publisher is responsible for the content of the notification.

EQS distribution services include legal reporting, corporate/financial news and press releases.
Media archive at https://eqs-news.com

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.